MedTrace Logo

Probiotics in Diabesity: A Pilot Study

NCT02469558 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2020-02-06

No results posted yet for this study

Summary

Obesity and type 2 diabetes are a pandemic disease leading to a high morbidity and mortality. Probiotic modulation of gut flora is a possible therapeutic mechanism.

The aim of this study is to investigate and compare thoroughly the effect of a multispecies probiotic on glycaemic control, gut microbiota and gut permeability in patients with metabolic syndrome and diabetes.

Conditions

Interventions

DIETARY_SUPPLEMENT

Winclove 851 and 110

prebiotic and probiotic mixture

DIETARY_SUPPLEMENT

Placebo

white powder without pro/probiotic

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Vanessa Stadlbauer-Köllner, MD · Medical University of Graz

  • Harald Sourij, MD · Medical University of Graz

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02469558 on ClinicalTrials.gov